Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

被引：7

作者：

Wight, Joel ^{[1
,2
,3
,4
]}

Hamad, Nada ^{[12
,13
,14
]}

Campbell, Belinda A. ^{[5
,7
,9
]}

Ku, Matthew ^{[8
]}

Lee, Kenneth ^{[15
,16
]}

Rose, Hannah ^{[10
,11
]}

Armytage, Tasman ^{[18
]}

Latimer, Maya ^{[19
,20
]}

Lee, Hui-Peng ^{[21
]}

Lee, Sze-Ting ^{[3
]}

Dickinson, Michael ^{[4
,6
,9
]}

Khor, Richard ^{[3
]}

Verner, Emma ^{[15
,17
]}

机构：

[1] James Cook Univ, Dept Haematol & Bone Marrow Transplantat, Townsville Univ Hosp, Townsville, Qld, Australia

[2] James Cook Univ, Sch Med, Townsville, Qld, Australia

[3] Univ Melbourne, Dept Haematol, Austin Hlth, Melbourne, Vic, Australia

[4] Univ Melbourne, Sch Med, Melbourne, Vic, Australia

[5] Univ Melbourne, Sch Med, Dept Radiat Oncol, Melbourne, Vic, Australia

[6] Univ Melbourne, Peter MacCallum Canc Ctr, Haematol, Melbourne, Vic, Australia

[7] Univ Melbourne, Dept Clin Pathol, Melbourne, Vic, Australia

[8] St Vincents Hosp, Dept Haematol, Melbourne, Vic, Australia

[9] Univ Melbourne, Dept Oncol, Parkville, Vic, Australia

[10] Deakin Univ, Dept Haematol, Univ Hosp, Geelong, Vic, Australia

[11] Deakin Univ, Sch Med, Geelong, Vic, Australia

[12] Univ Notre Dame, Dept Haematol, St Vincents Hosp, Notre Dame, IN USA

[13] Univ Notre Dame, Sch Med, Notre Dame, IN 46556 USA

[14] Univ New South Wales, St Vincents Clin Sch, Kensington, NSW, Australia

[15] Univ Sydney, Sch Med, Sydney, NSW, Australia

[16] Concord Repatriat Gen Hosp, NSW Hlth Pathol, Anat Pathol Dept, Sydney, NSW, Australia

[17] Concord Repatriat Gen Hosp, Dept Haematol, Sydney, NSW, Australia

[18] Gosford Hosp, Dept Haematol, Gosford, NSW, Australia

[19] Australian Natl Univ, Canberra Hosp, Dept Haematol, Canberra, ACT, Australia

[20] Australian Natl Univ, Dept Haematol, Canberra, ACT, Australia

[21] Flinders Med Ctr, Dept Haematol, Adelaide, SA, Australia

来源：

INTERNAL MEDICINE JOURNAL | 2022年 / 52卷 / 09期

关键词：

diffuse large B-cell lymphoma; diagnosis; prognosis; management; POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKIN-LYMPHOMA; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; INTERNATIONAL PROGNOSTIC INDEX; AGGRESSIVE NON-HODGKIN; HIGH-DOSE CHEMOTHERAPY; HIGH-RISK PATIENTS; BONE-MARROW-TRANSPLANTATION; SOUTHWEST-ONCOLOGY-GROUP; CHOP-LIKE CHEMOTHERAPY;

D O I：

10.1111/imj.15533

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.

引用

页码：1609 / 1623

页数：15

共 50 条

[21] Diffuse large B-cell lymphoma
Fuchs, David
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (01) : 7 - 11
[22] Diffuse large B-cell lymphoma
Barraclough, Allison
Hawkes, Eliza
Sehn, Laurie H.
Smith, Sonali M.
HEMATOLOGICAL ONCOLOGY, 2024, 42 (06)
[23] Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma
Cabanillas, Fernando
Shah, Bijal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (12) : 783 - 796
[24] ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma
Dabaja, Bouthaina S.
Advani, Ranjana
Hodgson, David C.
Dhakal, Sughosh
Flowers, Christopher R.
Ha, Chul S.
Hoppe, Bradford S.
Mendenhall, Nancy P.
Metzger, Monika L.
Plastaras, John P.
Roberts, Kenneth B.
Shapiro, Ronald
Smith, Sonali M.
Terezakis, Stephanie A.
Winkfield, Karen M.
Younes, Anas
Constine, Louis S.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (06): : 610 - 620
[25] Treatment strategies for patients with diffuse large B-cell lymphoma
Poletto, Stefano
Novo, Mattia
Paruzzo, Luca
Frascione, Pio Manlio Mirko
Vitolo, Umberto
CANCER TREATMENT REVIEWS, 2022, 110
[26] Advances in proteomics in diffuse large B-cell lymphoma (Review)
Guo, Zihan
Wang, Chenchen
Shi, Xinyi
Wang, Zixuan
Tao, Jingyi
Ma, Jiaying
Bi, Lintao
ONCOLOGY REPORTS, 2024, 51 (06)
[27] Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma
Harkins, R. Andrew
Chang, Andres
Patel, Sharvil P.
Lee, Michelle J.
Goldstein, Jordan S.
Merdan, Selin
Flowers, Christopher R.
Koff, Jean L.
EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (11) : 959 - 973
[28] B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma
Ci, Weimin
Polo, Jose M.
Melnick, Ari
CURRENT OPINION IN HEMATOLOGY, 2008, 15 (04) : 381 - 390
[29] Antibody and immunotherapy in diffuse large B-cell lymphoma
Barraclough, Allison
Hawkes, Eliza A.
SEMINARS IN HEMATOLOGY, 2023, 60 (05) : 338 - 345
[30] Palliative Radiotherapy for Diffuse Large B-cell Lymphoma
Wright, Christopher M.
Koroulakis, Antony I.
Baron, Jonathan A.
Chong, Elise A.
Tseng, Yolanda D.
Kurtz, Goldie
LaRiviere, Michael
Venigalla, Sriram
Jones, Joshua A.
Maity, Amit
Mohindra, Pranshu
Plastaras, John P.
Paydar, Ima
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10) : 650 - 658

← 1 2 3 4 5 →